Prediction of Response to Intra-articular Injections of Hyaluronic Acid for Knee Osteoarthritis
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to evaluate whether the investigators can develop a computer algorithm to predict which individual patients will respond to injections of hyaluronic acid (HA) products for knee osteoarthritis.
| Condition | Intervention | Phase |
|---|---|---|
|
Osteoarthritis, Knee |
Device: hylan G-F 20 Device: 1% sodium hyaluronate |
Phase 4 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Outcomes Assessor) |
| Official Title: | Prediction of Response to Intra-articular Injections of Hyaluronic Acid for Knee Osteoarthritis |
- Change from Baseline Knee injury and Osteoarthritis Outcome Score (KOOS)at 6 months [ Time Frame: 6 months ] [ Designated as safety issue: No ]The KOOS is 42-item patient-report questionnaire that assesses symptoms and problems associated with knee injury and osteoarthritis. It yields scores for five scales including Pain, Other Symptoms, Function in Daily Living, Function in Sport/Recreation, and Knee-Related Quality of Life.
- Change from Baseline Knee injury and Osteoarthritis Outcome Score (KOOS) at 12 months [ Time Frame: 12 months ] [ Designated as safety issue: No ]The KOOS is 42-item patient-report questionnaire that assesses symptoms and problems associated with knee injury and osteoarthritis. It yields scores for five scales including Pain, Other Symptoms, Function in Daily Living, Function in Sport/Recreation, and Knee-Related Quality of Life.
- Change from Baseline Visual Analogue Scale (VAS) at 6 months [ Time Frame: 6 months ] [ Designated as safety issue: No ]The VAS is a patient-reported assessment of knee pain. Patients mark on a line (0-100) their current level of knee pain while moving and while at rest.
- Change from Baseline Visual Analogue Scale (VAS) at 12 months [ Time Frame: 12 months ] [ Designated as safety issue: No ]The VAS is a patient-reported assessment of knee pain. Patients mark on a line (0-100) their current level of knee pain while moving and while at rest.
| Estimated Enrollment: | 250 |
| Study Start Date: | October 2008 |
| Estimated Study Completion Date: | December 2013 |
| Estimated Primary Completion Date: | December 2013 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Active Comparator: Synvisc (hylan G-F 20) |
Device: hylan G-F 20
Three 2 cc injections at weekly intervals
Other Name: Synvisc
|
| Active Comparator: Euflexxa (1% sodium hyaluronate) |
Device: 1% sodium hyaluronate
Three 2 cc injections at weekly intervals
Other Name: Euflexxa
|
Detailed Description:
Background Osteoarthritis (OA) of the knee is a debilitating condition that affects an estimated 21 million Americans. This number is expected to rise steadily as the population ages. The medical expenditures associated with arthritis and other rheumatic conditions in the United States have increased from $50 billion in 1997 to $86 billion in 2003. In 2003, almost 420,000 total knee replacements were performed, primarily for arthritis. Injections of hyaluronic acid (HA) have been shown to provide symptom relief for many OA patients who have failed to respond to conservative interventions. Many other patients, however, experience only slight or no improvement. The results from this study will allow physicians to identify whether a patient is likely or not likely to respond well to HA therapy leading to improved treatment success rates.
Goals This study has two related goals: 1) to identify patient and treatment factors that predict response to intra-articular injections of hyaluronic acid for knee osteoarthritis using multivariable analysis and 2) develop mathematical and statistical models that will predict individual patient response to HA for knee OA.
It is anticipated that the investigators will develop computer software in this study that can support clinical decision making related to viscosupplementation in the treatment of knee OA. If this project yields successful patient predictive models, physicians who are considering a trial of HA for a patient will have some empirical basis for treatment selection. Eventually a physician would be able to assess a relatively small number of variables for a patient and then be provided with predictions regarding treatment response.
**Please note that the study site at the Naval Medical Center in Portsmouth, Virginia can only enroll patients who are eligible to be treated at a military facility.
Eligibility| Ages Eligible for Study: | 18 Years to 65 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Symptomatic knee osteoarthritis presenting to physician's office
- Radiographic evidence of knee osteoarthritis
- Age 18 years or older
- Failed minimum of 3 months of non-operative treatment, including, but not limited to, Tylenol, anti-inflammatory medication, cortisone injection, physical therapy, bracing, and/or heel wedge
- Symptoms for at least 3 months
Exclusion Criteria:
- Associated ligamentous instability
- History of deep knee infection
- Candidate for total knee arthroplasty or arthroscopy
- Peripheral neuropathy.
- X-rays that are completely negative and only MRI evidence or arthroscopic evidence (from previous arthroscopy) of OA.
- Prior HA injections at any point in the past
- Chondrocalcinosis
- Patients with precautions or contraindications for viscosupplementation use
- Cortisone injection within past 3 months
Contacts and Locations| Contact: Bart Mann, PhD | 847-292-4900 | bart@aossm.org |
| United States, Michigan | |
| Henry Ford Medical Center | Recruiting |
| Novi, Michigan, United States, 48377-3600 | |
| Contact: Jennifer Schilling, BS 248-661-7131 JSCHILL2@hfhs.org | |
| Contact: Cheryl Grega, MSN, RN (248) 344-2417 CGREGA1@hfhs.org | |
| Principal Investigator: Patricia Kolowich, MD | |
| United States, Virginia | |
| Naval Medical Center Portsmouth (this site can only enroll patients who are eligible to be treated at a military facility) | Recruiting |
| Portsmouth, Virginia, United States, 23708-2197 | |
| Contact: Brittany Hart, BA 757-953-1826 Brittany.Hart.ctr@med.navy.mil | |
| Contact: Lorie Martin (757) 953-1875 Lorie.Martin.ctr@med.navy.mil | |
| Principal Investigator: Marlene DeMaio, MD | |
| Study Chair: | Robert Marx, MD | Hospital for Special Surgery, New York |
| Principal Investigator: | Marlene DeMaio, MD | United States Naval Medical Center, Portsmouth |
More Information
Additional Information:
No publications provided
| Responsible Party: | American Orthopaedic Society for Sports Medicine |
| ClinicalTrials.gov Identifier: | NCT01557868 History of Changes |
| Other Study ID Numbers: | AOSSM 51H |
| Study First Received: | March 12, 2012 |
| Last Updated: | August 1, 2012 |
| Health Authority: | United States: Institutional Review Board |
Additional relevant MeSH terms:
|
Osteoarthritis Osteoarthritis, Knee Arthritis Joint Diseases Musculoskeletal Diseases Rheumatic Diseases |
Hyaluronic Acid Adjuvants, Immunologic Immunologic Factors Physiological Effects of Drugs Pharmacologic Actions |
ClinicalTrials.gov processed this record on May 23, 2013